RSS   Newsletter   Contact   Advertise with us
Post Online Media

GlaxoSmithKline: Luke Miels appointed president, global pharmaceuticals

GSKGlaxoSmithKline plc announced that Luke Miels has been appointed president, global pharmaceuticals, GSK.

Mr. Miels is currently Executive Vice President of AstraZeneca’s European business and was previously EVP, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.

READ MORE GlaxoSmithKline CEO Sir Andrew Witty to retire in 2017

Over the course of his career, Mr. Miels has built highly effective strategic partnerships between R&D and the relevant commercial organisations to develop superior portfolio and product franchises at AstraZeneca, Roche and Sanofi-Aventis.

Mr. Miels has significant international experience having worked and lived in the US, China, Singapore, the UK and continental Europe.

At AstraZeneca, he has helped strengthen the company’s product portfolio, launching Tagrisso in the US, improving growth of the cardiovascular and metabolic portfolios, notably Brilinta, and through business development with investments in companies such as Acerta Pharma and the acquisition of ZS Pharma.

Mr. Miels joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division.

Before then, he held roles of increasing seniority at Sanofi-Aventis, including positions in Asia Pacific and the US. He also co-led the US integration of Sanofi and Aventis.

Mr. Miels began his career in 1995 as a Sales Representative and Product Manager with AstraZeneca in Australia.

He holds a BSc in biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.




What to read next



 LATEST MOVES FROM United Kingdom 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy